Now, there could be another alternative, in the form of eye drops administered daily, according to AbbVie's Allergan subsidiary, which reported new phase 3 data for its pilocarpine formulation ...
It was then that Actavis, a drug company that specializes in generic drugs and over-the-counter products, scooped up Allergan for a neat $66 billion. Here's a photo of Actavis CEO Brenton Saunders ...
Brin's been researching Botox since 1984 and is currently the chief scientific officer of Botox at the drug company Allergan. It's one of many Botox-related license plates he owns, including some ...
The spokesperson added: “Allergan wants its patents to be enforced against infringers, (makers of generic eye drops) but in federal court, not in the IPR proceedings.” The tribe runs a large ...
Paine, Lynn S., Suraj Srinivasan, John C. Coates, and David Lane. "The Allergan Board Under Fire (A)." Harvard Business School Case 316-010, January 2016. (Revised January 2019.) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results